We caught up with EASD President Prof. Stefano Del Prato (University of Pisa, Italy) to discuss the impact of the COVID-19 pandemic on the diabetes community and the latest emerging therapies in diabetes management.
Questions
- What have been the greatest challenges faced by the diabetes community during the COVID-19 pandemic? (0:30)
- What are the most exciting recent/emerging innovations in diabetes therapy? (2:01)
Disclosures: Stefano Del Prato has received grant/research support from AstraZeneca and Boehringer Ingelheim; has served on advisory boards for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk and Sanofi; and has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
